Noboru Yamamoto, MD

Department of Experimental Therapeutics, National Cancer Center Hospital
Tokyo, Tokyo, Japan

Disclosure information not submitted.

Presentation(s):

• Paper 23 - A PHASE IA/IB, DOSE-ESCALATION/EXPANSION STUDY OF THE MDM2-P53 ANTAGONIST BRIGIMADLIN (BI 907828) IN PATIENTS WITH SOLID TUMORS: SAFETY AND EFFICACY IN PATIENTS WITH LIPOSARCOMA

  Thursday, November 2, 2023
  4:00 PM – 5:30 PM